CytOSorb TreatMent Of Critically Ill PatientS Registry

ConditionsSeptic Shock Acute Respiratory Distress Syndrome Trauma Rhabdomyolysis Cardiogenic Shock Pancreatitis Acute on Chronic Liver Failure Acute Liver Failure Burns Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)Extracorporeal Life Support Postoperative Endocarditis Hemophagocytic Lymphohistiocytoses Liver Transplant; Complications Infectious Disease Postoperative Vasoplegic Syndrome Drug Overdose Sepsis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorCytoSorbents, Inc

About this trial

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Eligibility criteria

Qualifiers

Planned OR actual CytoSorb® 300 mL device utilization

Informed consent for prospective registry participation

Disqualifiers

Use of the CytoSorb® 300 mL device for antithrombotic removal only

Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only

The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.

Trial design

Treatments tested in this trial

CytoSorb

Treatment groups

No treatment groups listed

Locations28

Select a site below to view it on the map.

Austria

Germany

Italy

Poland

Portugal

Spain

Sponsors and collaborators

CytoSorbents, Inc

Lead sponsor

Source ClinicalTrials.gov